Home/Filings/4/0001209191-21-015852
4//SEC Filing

O'Grady Brendan P. 4

Accession 0001209191-21-015852

CIK 0000818686other

Filed

Mar 1, 7:00 PM ET

Accepted

Mar 2, 4:07 PM ET

Size

12.2 KB

Accession

0001209191-21-015852

Insider Transaction Report

Form 4
Period: 2021-02-28
O'Grady Brendan P.
EVP, North America Commercial
Transactions
  • Sale

    Ordinary Shares

    2021-03-01$10.83/sh9,849$106,67393,231.486 total
  • Sale

    Ordinary Shares

    2021-03-01$10.93/sh63,278$691,35029,953.486 total
  • Exercise/Conversion

    Ordinary Shares

    2021-02-28+24,934103,080.486 total
  • Exercise/Conversion

    Restricted Share Units

    2021-02-2824,93474,805 total
    Ordinary Shares (24,934 underlying)
Footnotes (7)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.78 to $11.01, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.905 to $10.980, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F7]Restricted share units were granted on February 28, 2020 with 24,934 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 24,937 vesting on February 28, 2024.

Issuer

TEVA PHARMACEUTICAL INDUSTRIES LTD

CIK 0000818686

Entity typeother

Related Parties

1
  • filerCIK 0001726533

Filing Metadata

Form type
4
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 4:07 PM ET
Size
12.2 KB